Nvidia Partners With GlaxoSmithKline to Use AI for Drug Development

Home / Nvidia Partners With GlaxoSmithKline to Use AI for Drug Development

Nvidia  (NVDA) – Get Report said Monday it was partnering with GlaxoSmithKline  (GSK) – Get Report and its artificial intelligence group to use AI for developing new drugs and vaccines, while building a supercomputer to aid researchers in their work on the coronavirus and other challenges.

Shares of Nvidia, the Santa Clara, Calif.-based computer graphics chip company, were up 3.4% to $540.08, while American depositary receipts of GlaxoSmithKline rose 1.5% to $37.79. 

Located in London, GSK’s hub will use biomedical data, AI methods and advanced computing platforms to unlock genetic and clinical data, Nvidia said.

The GSK AI hub will be home to its U.K.-based AI team, including GSK AI Fellows, a new professional training program and now scientists from Nvidia.

“GSK and Nvidia together will help push the boundaries of what AI can do and put vast data sources to work to advance the discovery of new medicines and vaccines,” Kimberly Powell, vice president of healthcare at Nvidia, said in a statement.

Source Article

, , , ,

About Author